


**PRODUCT: Acalabrutinib****ALTERNATE NAME:** (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide; ACP-196**CATALOG #:** B1193-5,25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C<sub>26</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>**MOLECULAR WEIGHT:** 465.52**CAS NUMBER:** 1420477-60-6**APPEARANCE:** Yellow Solid**SOLUBILITY:** DMSO**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20°C. Protect from air and light.**DESCRIPTION:** Acalabrutinib (ACP-196) is an orally available, selective irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. It is a second generation BTK inhibitor with improved pharmacological properties with better plasma exposure, oral absorption and shorter half-life. It prevents the activation of B-cell antigen receptor (BCR) signaling pathway, thus preventing B-cell activation and BTK mediated activation of downstream survival pathways.**REFERENCES:** Byrd, J.C., *et al.* (2016). *N Engl J Med.* **374**, 323-332**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**Acalabrutinib (**B1193-5,25**)AVL-292 (Spebrutinib) (**9413**)BTK Inhibitor, CNX-774 (**2600**)BTK Inhibitor, PCI-32765 (**2298**)CGI-1746 (**9647**)LFM-A13 (**2414**)RN-486 (**9678**)TP-0903 (**9590**)**USAGE:** **FOR RESEARCH CH USE ONLY! Not to be used in humans**